Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
01:41pm, Thursday, 09'th May 2024
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
01:12pm, Thursday, 09'th May 2024
Even after a slight price target reduction, the analyst feels the biotech's shares could see a major pop. In her view, management has devised the right strategy for developing its investigational prod
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript
10:57am, Wednesday, 08'th May 2024
Editas Medicine, Inc. (NASDAQ:EDIT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - C
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
09:25am, Wednesday, 08'th May 2024
Editas Medicine (EDIT) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.71 per share a year ago.
Editas Medicine Announces First Quarter 2024 Results and Business Updates
07:00am, Wednesday, 08'th May 2024
Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
07:00am, Thursday, 02'nd May 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wedn
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
08:00am, Wednesday, 01'st May 2024
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases Two-year extension for research and development of alpha-beta T cell
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
11:05am, Friday, 26'th Apr 2024
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentati
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
12:36pm, Friday, 29'th Mar 2024
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
07:58pm, Wednesday, 13'th Mar 2024
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
03:56pm, Tuesday, 12'th Mar 2024
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
03:31am, Thursday, 07'th Mar 2024
Editas Medicine just successfully navigated a key regulatory issue. Its reni-cel candidate now has a clearer path through its clinical trials.
Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)
05:05pm, Wednesday, 06'th Mar 2024
Editas Medicine, Inc. (NASDAQ:EDIT ) TD Cowen 44th Annual Healthcare Conference March 4, 2024 12:50 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Phi
